Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods
AssigneeAdheron Therapeutics, Inc.
InventorJames G. McArthur
Life of this patent
Estimating the term…
Abstract
The present invention relates to humanized antibodies that specifically bind an EC1 domain of a mammalian Cadherin-11 protein and compositions (e.g., pharmaceutical compositions) comprising such antibodies. The invention also relates to methods for treating Cadherin-11-mediated disorders in a mammalian subject by administering a therapeutically effective amount of a humanized antibody of the invention. Cadherin-11-mediated disorders suitable for treatment by the methods of the invention include inflammatory disorders (e.g., inflammatory joint disorders, such as rheumatoid arthritis), fibrosis and cancer.
Claims9
A humanized antibody that specifically binds EC1 domain of a mammalian Cadherin-11 protein and antagonizes said mammalian Cadherin-11 protein, comprising an antibody heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67 and SEQ ID NO:69.
A humanized antibody that specifically binds the EC1 domain of a mammalian Cadherin-11 protein and antagonizes said mammalian Cadherin-11 protein, comprising an antibody heavy chain variable region comprising SEQ ID NO:69 and an antibody light chain variable region comprising SEQ ID NO:71.
A pharmaceutical composition comprising a humanized antibody that specifically binds the EC 1 domain of a mammalian Cadherin-11 protein and antagonizes said mammalian Cadherin-11 protein, and a pharmaceutically-acceptable carrier, wherein the antibody comprises an antibody heavy chain variable region comprising SEQ ID NO:69 and antagonizes said mammalian Cadherin-11 protein.
Dependencies are inferred from the claim text.